sdz mrl 953 has been researched along with Neoplasms in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Engelhardt, R; Färber, L; Gaboriau, E; Galanos, C; Haus, U; Kiani, A; Knopf, HP; Mertelsmann, R; Otto, F; Seiz, A; Stütz, P; Tschiersch, A | 1 |
1 trial(s) available for sdz mrl 953 and Neoplasms
Article | Year |
---|---|
Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Toxins; Cytokines; Double-Blind Method; Down-Regulation; Endotoxins; Humans; Interleukin-1; Interleukin-6; Interleukin-8; Lipid A; Lipopolysaccharides; Middle Aged; Neoplasms; Neutrophils; Prospective Studies; Salmonella; Tumor Necrosis Factor-alpha | 1997 |